- Trials with a EudraCT protocol (4,689)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,689 result(s) found for: Cysts.
Displaying page 127 of 235.
| EudraCT Number: 2021-005005-28 | Sponsor Protocol Number: ADENOFERT | Start Date*: 2022-11-08 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
| Full Title: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial featu... | |||||||||||||
| Medical condition: Women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis and women without adenomyosis but with similar baseline reproductive risks | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-004135-89 | Sponsor Protocol Number: D516FC00001 | Start Date*: 2022-04-07 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Sta... | |||||||||||||
| Medical condition: Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) DE (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003939-30 | Sponsor Protocol Number: CA209-142 | Start Date*: 2014-03-21 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer | |||||||||||||
| Medical condition: MSI Positive Colorectal Cancer MSI Negative Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) BE (Trial now transitioned) IE (Completed) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-005377-31 | Sponsor Protocol Number: ISRCTN45751386 | Start Date*: 2016-01-20 | |||||||||||
| Sponsor Name:HYKS Naistensairaala | |||||||||||||
| Full Title: Randomized trial of treatment and follow-up of vaginal intraepithelial neoplasia (VAIN) | |||||||||||||
| Medical condition: VAIN, vaginal intraepithelial neoplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000746-59 | Sponsor Protocol Number: ISRCTN23349576 | Start Date*: 2016-02-18 | |||||||||||
| Sponsor Name:HYKS Naistensairaala | |||||||||||||
| Full Title: Randomized trial of treatment of vaginal intraepithelial neoplasia (VAIN). | |||||||||||||
| Medical condition: VAIN, vaginal intraepithelial neoplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003415-26 | Sponsor Protocol Number: 2021-003415-26 | Start Date*: 2022-01-07 | ||||||||||||||||||||||||||
| Sponsor Name:Department of Oncology, Rigshospitalet | ||||||||||||||||||||||||||||
| Full Title: HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients | ||||||||||||||||||||||||||||
| Medical condition: HER2 positive Esophageal Squamous Cell Carcinoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2022-001157-23 | Sponsor Protocol Number: GO44096 | Start Date*: 2023-01-03 | |||||||||||
| Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF THE INTRAVENOUS FIXED-DOSE COMBINATION (IV FDC) OF TIRAGOLUMAB AND ATEZOLIZUMAB IN PARTICIPANTS WITH LOCALLY A... | |||||||||||||
| Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Trial now transitioned) CY (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000547-24 | Sponsor Protocol Number: CCRG11-001 | Start Date*: 2012-02-27 | ||||||||||||||||
| Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
| Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study | ||||||||||||||||||
| Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-004239-35 | Sponsor Protocol Number: 2017/16 | Start Date*: 2019-09-26 | |||||||||||
| Sponsor Name:Centre Antoine Lacassagne | |||||||||||||
| Full Title: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas | |||||||||||||
| Medical condition: Soft tissue sarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004624-41 | Sponsor Protocol Number: 24092020 | Start Date*: 2021-07-07 | ||||||||||||||||
| Sponsor Name:Zealand University Hospital | ||||||||||||||||||
| Full Title: Calcium Electroporation for Malignant GI Bleeding – a randomized controlled trial | ||||||||||||||||||
| Medical condition: Malignant gastrointestinal bleeding | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-004862-32 | Sponsor Protocol Number: IEO883/13F | Start Date*: 2014-10-22 | |||||||||||
| Sponsor Name:Istituto Europeo Oncologia | |||||||||||||
| Full Title: A Randomized Phase II Trial of Low Dose Aspirin versus Placebo in High-Risk Individuals with CT Screen Detected Subsolid Lung Nodules. | |||||||||||||
| Medical condition: Lung cancer increased risk in current or former heavy smokers, with CT SCAN screen detected subsolid lung nodules (Cosmos Project) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-003199-27 | Sponsor Protocol Number: STYLE | Start Date*: 2016-11-17 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
| Full Title: PHASE II TRIAL OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN SECOND AND FURTHER LINES | |||||||||||||
| Medical condition: B3 thimoma or thymic carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005730-20 | Sponsor Protocol Number: G.04.2011 | Start Date*: 2011-12-19 | |||||||||||
| Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA | |||||||||||||
| Full Title: Maintenance treatment with Lanreotide in Patients with small cell lung cancer (LD/ED) expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapy | |||||||||||||
| Medical condition: Small cell lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001970-16 | Sponsor Protocol Number: ARPA | Start Date*: 2016-01-15 | |||||||||||
| Sponsor Name:ASSOCIAZIONE PIEMONTESE DI ONCOLOGIA TORACICA (APOT) | |||||||||||||
| Full Title: A Phase II, Open-Label, Single Institution Observational Study to Assess the Tolerability and Impact on Quality of Life of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) who h... | |||||||||||||
| Medical condition: Subjects with EGFRm+/T790M, locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR-TKI | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-005129-22 | Sponsor Protocol Number: FIL_BRB | Start Date*: 2014-06-09 | |||||||||||
| Sponsor Name:Fondazione Italiana Linfomi | |||||||||||||
| Full Title: FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN –BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS AT FIRST RELAPSE | |||||||||||||
| Medical condition: NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003256-20 | Sponsor Protocol Number: FIL_RecAnz | Start Date*: 2015-07-07 | |||||||||||
| Sponsor Name:Fondazione Italiana Linfomi | |||||||||||||
| Full Title: A PHASE II PROSPECTIVE STUDY OF HIGH-DOSE myeloablative therapy, WITH STEM CELL DEVICES SUPPORT IN ELDERLY PATIENTS (from 65 to 76 years) with relapsed aggressive non-Hodgkin lymphoma OR RESISTANT... | |||||||||||||
| Medical condition: Non Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003447-34 | Sponsor Protocol Number: REQ-0000020479 | Start Date*: 2019-04-03 | |||||||||||
| Sponsor Name:Hellenic Genitourinary Cancer Group (HGUCG) | |||||||||||||
| Full Title: Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study | |||||||||||||
| Medical condition: muscle-invasive bladder cancer (MIBC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2023-000138-13 | Sponsor Protocol Number: CITATION | Start Date*: 2023-04-05 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
| Full Title: Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational s... | |||||||||||||
| Medical condition: Locally advanced cholangiocarcinoma patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001206-29 | Sponsor Protocol Number: ShorTrip | Start Date*: 2021-07-22 | |||||||||||
| Sponsor Name:Fondazione GONO | |||||||||||||
| Full Title: ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer. | |||||||||||||
| Medical condition: Locally advanced rectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001203-32 | Sponsor Protocol Number: DEDALUS | Start Date*: 2021-10-25 | |||||||||||
| Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
| Full Title: An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypo-fractionated RT and maintenance immunotherapy for stage III unresectable Non –small-cell lung carcino... | |||||||||||||
| Medical condition: stage III unresectable non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.